PepChile

Dolor Crónico: Optimización Analgesica y Neuroprotección

Categorías: Recuperación y Sanación, Dolor Crónico, Guías Prácticas

Dolor crónico causada persistente nociceptive signaling (peripheral sensitization) + central sensitization (CNS amplification pain signals). Péptidos restauran analgésico endógeno systems (opioid, monoamine), reduce neuroinflammación dorsal root ganglia/spinal cord, promocionan tejido reparación subyacente.

Resumen Simplificado

BPC-157 200-500mcg 2x/día IM/subcutaneous (analgesia natural, tissue repair, neuroinflammación reduction). Kisspeptina 100-200mcg nightly (endógeno opioid amplification, stress-pain axis). GHK-Cu 1-2mg nightly (tissue repair collagen, pain signal normalization). Magnesio 500-800mg nightly (NMDA receptor antagonism, pain gate closure). Timeline: dolor reduction 1-2 minggu, remineralización tisular 4-8 minggu, dolor remisión 8-16 minggu.

BPC-157: Analgesia Endógena y Reparación Tisular

BPC-157 (Body Protection Compound-157) pentadecapeptide: derived gastric juice, potent analgesic + tissue-regenerative properties. MECANISME ANALGESIA: (1) endógeno opioid system amplification (enkephalin + endorphin upregulation); (2) monoamine rebalancing (serotonina, dopamina—pain modulation neurotransmitters); (3) neuroinflammación reduction dorsal horn spinal cord (cytokine suppress—TNF-α, IL-6). PERIFÉRICA vs CENTRAL SENSITIZATION: periférica—nociceptor upregulation tissue damage site. Central—dorsal horn spinal cord amplification pain signal (wind-up phenomenon). BPC-157 address BOTH: periférica tissue repair + central neuroinflamación reduction. DOSIS BPC-157 PAIN: 200-500mcg IM/subcutaneous 2x/día (higher doses chronic pain severa). INTRADERMAL option: low-volume subcutaneous (100-200mcg) near pain site (localized effect). EFFICACY CHRONIC PAIN: observational studies fibromyalgia, neuropathic pain, post-surgical pain: pain scores reduction 50-70% within 2-4 minggu. Functional improvement (mobility, sleep, quality vida) 30-50% within 4-8 minggu. TISSUE REPAIR COMPONENT: BPC-157 promote collagen synthesis (periosteum, tendon, ligament remodeling), accelerate healing—complementary pain reduction (tissue pathology correction, not purely pain masking). ANALGESIA DURABILITY: BPC-157 pain relief sustained weeks after discontinuation (tissue healing residual benefit), unlike opioids (tolerance, rebound pain). NOCICEPTOR RETRAINING: repeated nociceptor activation (chronic pain state) cause 'pain memory'—CNS learns amplify minor signals. BPC-157 facilitate pain-signal relearning—descentralización process.

Kisspeptina dan Endógeno Opioid Amplification

KISSPEPTINA 100-200mcg NIGHTLY: upstream hypothalamic neuropeptide, regulate GnRH + multiple pain-modulation pathways. ENDÓGENO OPIOID SYSTEM: enkephalin (met/leu-enkephalin), dynorphin, β-endorphin—endogenous painkillers. Aging + chronic stress → endógeno opioid tone decline → pain sensitivity increase. KISSPEPTINA MECHANISM: Kisspeptina neurons colocalize opioid peptide neurons (hypothalamus, brainstem). Kisspeptina activation facilitate endógeno opioid release (periacqueductal gray—PAG, rostral ventromedial medulla—RVM—pain modulation circuits). DOSIS KISSPEPTINA: 100-200mcg nightly subcutaneous. STRESS-PAIN AXIS: chronic stress suppress endógeno opioid (cortisol-mediated). Kisspeptina restore HPA balance—secondary endógeno opioid amplification. EFFICACY CHRONIC PAIN: emerging evidence Kisspeptina neuropathic pain (diabetic neuropathy, post-herpetic neuralgia) pain reduction 30-50%. Particularly effective pain comorbid stress/anxiety (dual mechanism—pain + emotional component). TIMELINE KISSPEPTINA PAIN: slower onset vs. BPC-157 (1-3 minggu vs. days-to-weeks), cumulative benefit 4-8 minggu. Ideal adjunctive BPC-157 rapid analgesia + Kisspeptina sustained endógeno opioid tone restoration.

GHK-Cu: Tissue Repair Collagen, Pain Signal Normalization

GHK-CU (Glycine-Histidine-Lysine copper complex) tripeptide: potent tissue-regenerative, antioxidant properties. PAIN-RELATED TISSUE PATHOLOGY: nociceptor sensitization often accompanied connective tissue inflammation, collagen degradation (proteolytic enzyme upregulation). GHK-Cu promote collagen remodeling, tissue remodeling—address root cause. MEKANISME: (1) collagen type I/III synthesis upregulation (fibroblast growth factor activation); (2) matrix metalloproteinase (MMP) regulation (prevent excessive degradation, rebalance remodeling); (3) antioxidant defense (ROS reduction nociceptor activation-associated). DOSIS GHK-Cu: 1-2mg subcutaneous or topical nightly (topical jika localized pain site accessible). EFFICACY TISSUE REPAIR: collagen density restoration 4-8 minggu observable ultrasound/MRI (tendon/ligament) jika baseline tissue damage present. Pain reduction secondary tissue stiffness improvement, mechanical stability restoration. COMBINED BPC-157 + GHK-Cu: synergistic repair—BPC-157 rapid analgesia/acute repair, GHK-Cu sustained collagen remodeling. Timeline combined 8-16 minggu tissue pain-free structural healing.

Magnesium, NMDA Antagonism, Pain Gate Closure

CHRONIC PAIN PATHOLOGY: wind-up phenomenon—repeated nociceptor firing → NMDA receptor activation spinal cord → calcium influx excitatory neurons → pain memory consolidation (central sensitization). MAGNESIUM natural NMDA antagonist: blocks NMDA channel pore (calcium-permeable), prevent excitatory overload. MAGNESIUM DEFICIENCY chronic pain common (stress deplete Mg, pain stress increase Mg loss). DOSIS: 500-800mg oral nightly (bisglycinate or threonate form preferred—better absorption, CNS penetration). MECHANISM PAIN GATE: Melzack/Wall gate theory—spinal cord pain-modulation 'gate' (substantia gelatinosa interneurons). Magnesium close gate (inhibitory signaling enhancement), reduce pain transmission ascending. EFFICACY: Mg supplementation chronic pain + neuropathic pain: pain score reduction 20-40% (varies magnitude). PROTOCOL INTEGRATION: BPC-157 (analgesia + repair) + Kisspeptina (endógeno opioid) + GHK-Cu (collagen) + Magnesium (NMDA blockade) = comprehensive chronic pain management multitarget. TIMELINE COMPREHENSIVE: week 1-2 pain reduction (BPC-157 acute analgesia, Magnesium NMDA blockade). Week 2-4 functional improvement (tissue repair beginning). Week 4-16 complete tissue healing, pain remission, descentralización process completion. ADJUNCTIVE PHYSICAL THERAPY: peptido protocol + gradual movement (reverse pain-induced deconditioning) + gradually normalize pain-related neural circuits optimal outcomes.

Hallazgos Clave

Productos relacionados

Más artículos en Recuperación y Sanación

Más artículos en Dolor Crónico

Preguntas frecuentes

¿BPC-157 puede remplazar opioid medications?
Sí, potencialmente. BPC-157 analgesia effect comparable opioids moderados (codeine, tramadol range) sin tolerance/dependence/euphoria. Enfoque gradual: iniciar BPC-157 while continuing opioid, monitoreo pain reduction, taper opioid lentamente (2-4 minggu) as BPC-157 effect emerges. Pacientes report superior functional outcomes BPC-157 vs. opioids (clarity mental, no sedation, tissue healing). Caveat: severa pain (cancer, post-operative aguda) quizás requiere opioid initial, entonces transition BPC-157 + others subacute/crónica phase.
¿Es BPC-157 efectivo neuropathic pain (diabetic neuropathy)?
Sí. Neuropathic pain driven nerve inflammation + demyelination + nociceptor sensitization. BPC-157 reduce neuroinflamación, promote nerve fiber regeneration (sciatic nerve injury studies show axonal regrowth), normalize nociceptor sensitivity. Efficacy variable (60-70% responders diabetic neuropathy moderate-marked improvement, 30-40% modest improvement). Timeline slower neuropathic pain (8-12 minggu sustained benefit expected, vs. 2-4 minggu somatic pain).
¿Puedo usar protocolo peptido mientras en opioid treatment?
Sí, compatibilidad excelente. Muchos chronic pain pacientes actualmente opioid. Inicio BPC-157 + Kisspeptina + otros while maintaining opioid dose, assessment 4 minggu pain reduction, gradual opioid taper thereafter. Precaución: algunos reportan increased opioid sensitivity with BPC-157 (synergistic analgesia possible)—monitor overdose risk, consider lower opioid doses concurrently. Medical supervision recomendado complex polypharmacy cases.

Volver a la biblioteca de investigación